CANADIAN CANCER TRIALS GROUP
BRAIN
DISEASE SITE COMMITTEE MEETING AGENDA
OPEN SESSIONS
Venue: CARLYLE
Date: Saturday, April 29th 2017
Time: 9:00 am – 12:00 p.m.
Chair: Dr. Warren Mason

9:00 am   Welcome and Introductions

9:05 am   Summary of results from the CCSRI Grant review
          W. Mason

Brief Updates on Completed Studies & Studies Closed to Accrual

9:15 am   CE.6: A Randomized Phase III Study of Temozolomide a Short-Course Radiation versus Short-Course Radiation Alone in the Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients-manuscript published
          J. Perry & N. Laperriere

          CEC.1 (EORTC 26053_22054): Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19Q Deleted Anaplastic Glioma.
          The CATNON Intergroup Trial-manuscript status
          W. Mason & C. O'Callaghan

          CE.5 (EORTC 22033-26033): Primary Chemotherapy with Temozolomide vs Radiotherapy in Patients with Low-Grade Gliomas After Stratification for Genetic 1P Loss: A Phase III Study – manuscript published
          W. Mason

Actively Accruing Trials

9:30 am   CEC.6 (NCCTG N0577): Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma
          C. O'Callaghan

9:40 am   IND.222: A phase I/II trial of AZD2014 with temozolomide in patients with GBM at first progression
          W. Mason
Newly Approved/Opened CCTG Trials

9:50 am  **CEC.5 (ALLIANCE 221208)**: Randomized Phase II Study: Corticosteroids + Bevacizumab vs Corticosteroids + Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases  

C. Chung

10:00 am  **CEC.3 (NCCTG N107C) *closed***: A phase III trial of post-surgical stereotactic radiosurgery compared with whole brain radiotherapy (WBRT) for resected metastatic brain disease  

D. Roberge

CE.7: A Phase III Trial of Stereotactic Radiosurgery compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases  

D. Roberge

10:15-10:30 am  Coffee Break

Miscellaneous

10:30 am  Stand up to Cancer Canada Brain Tumour Research Grant: Status Report  

P. Dirks

10:55am  Potential future trial: A phase III trial of the pan-proteosome inhibitor Marizomib with Radiotherapy and Temozolomide for newly-diagnosed GBM

- Marizomib: Background, rational for evaluation in GBM, pre-clinical data, overview of completed and ongoing phase I/II trials of agent in recurrent and newly-diagnosed GBM  
  M. Trikha

- Proposed EORTC phase III trial design in newly-diagnosed GBM  
  W. Mason

11:20 am  Normograms for predicting survival of elderly patients with glioblastoma: A prognostic factors analysis based on CE.6  

F. Moraes

11:45 am  Report from IND Committee  

M. Pitz

12:00 pm  **Closing Remarks**